Zacks Investment Ideas feature highlights: Eli Lilly, Eaton and Interactive Brokers

The 2025 Q2 earnings season highlighted strong performance from key companies, with Eli Lilly (LLY) reporting a 38% YoY sales increase to $15.5 billion, driven by Zepbound and Mounjaro, prompting raised FY25 guidance. Interactive Brokers (IBKR) demonstrated significant platform expansion, with customer accounts growing 32% and commission revenue up 27% due to elevated trading volumes. Eaton (ETN) achieved record Q2 adjusted EPS of $2.95 and 8% organic sales growth, capitalizing on AI-related demand in its power management segment, collectively signaling robust operational strength and positive outlooks across diverse sectors.

Analysis

The Q2 2025 earnings season underscored robust fundamental performance across diverse sectors, exemplified by Eli Lilly (LLY), Interactive Brokers (IBKR), and Eaton (ETN). Eli Lilly reported a significant 38% year-over-year sales increase to $15.5 billion, beating consensus estimates by 6%, primarily driven by exceptional volume growth in Zepbound (+172%) and Mounjaro (+68%). This top-line strength translated to improved profitability, with gross margin expanding to 84.3% from 80.8% a year prior, prompting an upward revision of its full-year 2025 revenue and adjusted EPS guidance. Despite LLY's stock being down 5% year-to-date, these results, coupled with insider buying, suggest a potential inflection point. Concurrently, Interactive Brokers demonstrated powerful platform momentum, with customer accounts growing 32% year-over-year to 3.9 million. This user expansion directly fueled a 27% rise in commission revenue to $516 million, supported by double-digit increases in trading volumes across all major asset classes and validating the stock's 110% appreciation over the past year. Eaton leveraged the AI infrastructure build-out, achieving record Q2 adjusted EPS of $2.95 (+8% YoY) and record segment margins of 23.9% on the back of 8% organic sales growth, signaling strong demand and operational efficiency in its power management business. The company also reinforced its appeal to income-focused investors with a 7.5% five-year annualized dividend growth rate.

Key Decisions for Investors

• For Eli Lilly, the significant disconnect between its year-to-date stock underperformance and its accelerating fundamental growth, evidenced by a 38% sales jump and raised FY25 guidance, may present a compelling entry point for growth-oriented investors.
• Investors should recognize Interactive Brokers' 110% stock appreciation is substantiated by strong operational metrics, including a 32% increase in customer accounts, suggesting its rally is based on fundamental market share capture rather than pure speculation.
• Eaton presents a dual-thesis investment, offering exposure to the secular AI data center trend through its record profitability and backlog, while simultaneously providing a defensive income component via its long-standing dividend, which has a 7.5% five-year annualized growth rate.
• Given the strong, distinct drivers for each company—pharmaceutical innovation at LLY, platform growth at IBKR, and industrial AI exposure at ETN—investors should consider that leadership and alpha generation are present across multiple sectors, not just concentrated in one market theme.